Symptomatic Bradycardia Due to Alectinib in a Patient with Advanced Stage of NSCLC
Alectinib is one of the targeted therapies commonly given to patients with advanced non-small cell lung cancer (NSCLC) with mutations in the ALK gene. The most common adverse effects of alectinib are fatigue, constipation, edema, myalgia and anemia. Meanwhile, bradycardia was reported as a very comm...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Interna Publishing
2022-07-01
|
| Series: | Acta Medica Indonesiana |
| Subjects: | |
| Online Access: | http://www.actamedindones.org/index.php/ijim/article/view/2095 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849320709449318400 |
|---|---|
| author | Ceva Wicaksono Pitoyo Cleopas Martin Rumende Anindita Kartika Wiraputri Fatira Ratri Audita |
| author_facet | Ceva Wicaksono Pitoyo Cleopas Martin Rumende Anindita Kartika Wiraputri Fatira Ratri Audita |
| author_sort | Ceva Wicaksono Pitoyo |
| collection | DOAJ |
| description | Alectinib is one of the targeted therapies commonly given to patients with advanced non-small cell lung cancer (NSCLC) with mutations in the ALK gene. The most common adverse effects of alectinib are fatigue, constipation, edema, myalgia and anemia. Meanwhile, bradycardia was reported as a very common adverse effect, but generally asymptomatic, unlike the reported patient in this case report. This case report’s purpose is to increase awareness of the possibility of adverse effects due to alectinib administration that require immediate intervention in order to improve the quality of life and patient survival, especially in patients with advanced NSCLC.
|
| format | Article |
| id | doaj-art-17228a26e47b4ca499c8d1637af5dba5 |
| institution | Kabale University |
| issn | 0125-9326 2338-2732 |
| language | English |
| publishDate | 2022-07-01 |
| publisher | Interna Publishing |
| record_format | Article |
| series | Acta Medica Indonesiana |
| spelling | doaj-art-17228a26e47b4ca499c8d1637af5dba52025-08-20T03:50:00ZengInterna PublishingActa Medica Indonesiana0125-93262338-27322022-07-01542Symptomatic Bradycardia Due to Alectinib in a Patient with Advanced Stage of NSCLCCeva Wicaksono Pitoyo0Cleopas Martin Rumende1Anindita Kartika Wiraputri2Fatira Ratri Audita3Division of Respirology and Critical Care Internal Medicine, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia - Cipto Mangunkusumo Hospital, Jakarta, Indonesia.Division of Respirology and Critical Care Internal Medicine, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia - Cipto Mangunkusumo Hospital, Jakarta, Indonesia.Division of Respirology and Critical Care Internal Medicine, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia - Cipto Mangunkusumo Hospital, Jakarta, Indonesia.Division of Respirology and Critical Care Internal Medicine, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia - Cipto Mangunkusumo Hospital, Jakarta, Indonesia.Alectinib is one of the targeted therapies commonly given to patients with advanced non-small cell lung cancer (NSCLC) with mutations in the ALK gene. The most common adverse effects of alectinib are fatigue, constipation, edema, myalgia and anemia. Meanwhile, bradycardia was reported as a very common adverse effect, but generally asymptomatic, unlike the reported patient in this case report. This case report’s purpose is to increase awareness of the possibility of adverse effects due to alectinib administration that require immediate intervention in order to improve the quality of life and patient survival, especially in patients with advanced NSCLC. http://www.actamedindones.org/index.php/ijim/article/view/2095alectinibbradycardiaNSCLC |
| spellingShingle | Ceva Wicaksono Pitoyo Cleopas Martin Rumende Anindita Kartika Wiraputri Fatira Ratri Audita Symptomatic Bradycardia Due to Alectinib in a Patient with Advanced Stage of NSCLC Acta Medica Indonesiana alectinib bradycardia NSCLC |
| title | Symptomatic Bradycardia Due to Alectinib in a Patient with Advanced Stage of NSCLC |
| title_full | Symptomatic Bradycardia Due to Alectinib in a Patient with Advanced Stage of NSCLC |
| title_fullStr | Symptomatic Bradycardia Due to Alectinib in a Patient with Advanced Stage of NSCLC |
| title_full_unstemmed | Symptomatic Bradycardia Due to Alectinib in a Patient with Advanced Stage of NSCLC |
| title_short | Symptomatic Bradycardia Due to Alectinib in a Patient with Advanced Stage of NSCLC |
| title_sort | symptomatic bradycardia due to alectinib in a patient with advanced stage of nsclc |
| topic | alectinib bradycardia NSCLC |
| url | http://www.actamedindones.org/index.php/ijim/article/view/2095 |
| work_keys_str_mv | AT cevawicaksonopitoyo symptomaticbradycardiaduetoalectinibinapatientwithadvancedstageofnsclc AT cleopasmartinrumende symptomaticbradycardiaduetoalectinibinapatientwithadvancedstageofnsclc AT aninditakartikawiraputri symptomaticbradycardiaduetoalectinibinapatientwithadvancedstageofnsclc AT fatiraratriaudita symptomaticbradycardiaduetoalectinibinapatientwithadvancedstageofnsclc |